Drug Trial Radar · NCT03123406
Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT
Last checked: Nov 20, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
750
Actual
Start
Apr 19, 2017
Primary completion
Apr 20, 2019
Study completion Sep 6, 2019
Sponsor
- Lead sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL in hemodialysis subjects with mild, moderate and severe SHPT; 2. To explore the impact of Cinacalcet HCL using on the combined use of drugs; 3. To explore the difference of patients who continued or discontinued Cinacalcet HCL in real-world period from 33rd to 52nd week.
Conditions
- Hyperparathyroidism; Secondary, Renal
Interventions
Cinacalcet HClDrug
Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compared with baseline data, the proportion of subjects reaching iPTH target at 20th weekTime frame: 20 weeks
- Compared with baseline data, the proportion of subjects reaching iPTH target at 32nd weekTime frame: 32 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Jinling Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.